BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12111132)

  • 1. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of efficacy and clinical impact of FDG-PET in patients with suspicion of recurrent colorectal cancer].
    Borrego Dorado I; Gómez Camarero P; Ruiz Franco-Baux J; Vázquez Albertino R
    Rev Esp Med Nucl; 2004; 23(5):313-23. PubMed ID: 15450136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.
    Imdahl A; Reinhardt MJ; Nitzsche EU; Mix M; Dingeldey A; Einert A; Baier P; Farthmann EH
    Langenbecks Arch Surg; 2000 Mar; 385(2):129-34. PubMed ID: 10796051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
    Ito K; Kato T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):270-7. PubMed ID: 12073633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
    Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
    J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
    Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
    J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet.
    Zealley IA; Skehan SJ; Rawlinson J; Coates G; Nahmias C; Somers S
    Radiographics; 2001 Oct; 21 Spec No():S55-69. PubMed ID: 11598248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
    Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer.
    Simó M; Lomeña F; Setoain J; Pérez G; Castellucci P; Costansa JM; Setoain-Quinquer J; Doménech-Torné F; Carrió I
    Nucl Med Commun; 2002 Oct; 23(10):975-82. PubMed ID: 12352596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
    Strasberg SM; Dehdashti F
    J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.